ATEM (Alvesco Non-interventional Study)

AstraZeneca400 enrolled

Overview

The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season. Alvesco will be inhaled by a metered-dose inhaler. The study will provide further data on safety and tolerability of Alvesco .

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Asthma Allergy

Interventions

AlvescoDRUG

This is an observational study. Therefore, the physician decides about dosage according to individual needs.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Main Inclusion Criteria: * Asthma with or without allergic components Main Exclusion Criteria: * Hypersensitive to compounds of Alvesco * Other criteria as defined in the Summary of Product Characteristics, Chapter 4.3

Locations (79)

Outcomes

Primary Outcomes

Treatment success with Alvesco

Pre-/ post comparison of FEV1, Quality of life, Patient Questionnaire

Time frame: after 3 months

Secondary Outcomes

Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Time frame: after 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Nycomed Pharma GmbH

Amstetten, Austria

Nycomed Pharma GmbH

Baden, Austria

Nycomed Pharma GmbH

Bludenz, Austria

Nycomed Pharma GmbH

Böhlerwerk, Austria

Nycomed Pharma GmbH

Braunau am Inn, Austria

Nycomed Pharma GmbH

Bregenz, Austria

Nycomed Pharma GmbH

Dornbirn, Austria

Nycomed Pharma GmbH

Enns, Austria

Nycomed Pharma GmbH

Feldbach, Austria

Nycomed Pharma GmbH

Feldkirch, Austria

...and 69 more locations